Published in Drug Week, June 24th, 2011
"Dalotuzumab (MK-0646) is a recombinant humanized IgG(1) monoclonal antibody that binds specifically to CD221. It is currently in clinical development for the treatment of a wide variety of malignancies, such as cancers of the breast,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.